In Lancet Oncology this week:
An update of the 2x2 trial of tam and RT for locally excised DCIS is published, confirming the benefit of RT in reducing both non-invasive and invasive disease. Similarly tamoxifen is confirmed to benefit ipisilateral DCIS and contralateral disease, though not ipsilateral invasive recurrence. One of the things that is interesting in this trial, though it is a subgroup analysis, is that the benefit of tamoxifen in ipsilateral recurrences was largely seen in the absence of radiotherapy (see the forest plot on figure 3). Another gratifying conclusion is that there were no increases in contralateral breast events with RT due to carcinogenesis.
[Articles] Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial: "This updated analysis confirms the long-term beneficial effect of radiotherapy and reports a benefit for tamoxifen in reducing local and contralateral new breast events for women with DCIS treated by complete local excision."